1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Mental health is a major focus of the recent healthcare policy in the US. Conditions such as Alzheimer’s disease (AD), traumatic brain injury (TBI), PTSD, and other neurological conditions are at the forefront of current science in response to the wealth of unmet needs in both therapeutic options and overall support and care.

Scope

- Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Schizophrenia market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in US.

Table Of Contents

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis 16
4.1.1 Subjective Assessments 17
4.1.2 Disease Subtypes 18
4.2 Treatment Overview 21
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 23
4.2.2 Maintenance Treatment of Schizophrenia 24
4.3 US 25
4.3.1 Diagnosis 25
4.3.2 Clinical Practice 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles by Generation 29
5.3.1 Conventional Antipsychotics 29
5.3.2 Atypical Antipsychotics 32
6 Opportunity and Unmet Need 65
6.1 Unmet Needs Overview 65
6.1.1 Public Awareness 66
6.1.2 Early Diagnosis and Treatment 68
6.1.3 Long-Acting and Advanced Drug Delivery Systems 69
6.1.4 Effective Management of Negative and Cognitive Symptom Domains 70
6.2 Gap Analysis 71
6.2.1 Long-Acting Drug Delivery 72
6.2.2 Treatment of Negative and Cognitive Symptoms 72
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Early-Stage Pipeline Assessment 73
7.3 Novel Therapeutic Approaches 74
7.3.1 Negative Symptoms 75
7.3.2 Cognitive Symptoms 75
7.4 Long-Acting Drug Delivery 75
7.5 Technology Trends Analysis 76
7.6 Key Drugs in Clinical Development 77
7.6.1 Aripiprazole Lauroxil 78
7.6.2 Cariprazine 83
7.6.3 Brexpiprazole 87
7.6.4 Zicronapine 90
7.6.5 Bitopertin 93
7.6.6 EVP-6124 96
8 Market Outlook 100
8.1 US 100
8.1.1 Forecast 100
8.1.2 Key Events 103
8.1.3 Drivers and Barriers 103
9 Appendix 106
9.1 Bibliography 106
9.2 Abbreviations 115
9.3 Methodology 120
9.4 Forecasting Methodology 120
9.4.1 Diagnosis and Treatment Rates 120
9.4.2 Adherence Rates 121
9.4.3 Drugs Included in Each Therapeutic Class 121
9.4.4 Launch and Patent Expiry Dates 122
9.4.5 General Pricing Assumptions 123
9.4.6 Drug Assumptions 124
9.4.7 Generic Erosion 129
9.4.8 Pricing of Pipeline Agents 129
9.5 Key Opinion Leaders 131
9.6 About the Authors 132
9.6.1 Author 132
9.7 About GlobalData 133
9.8 Disclaimer 133

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 15
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 18
Table 3: Development-Based Classification of Antipsychotic Drugs 21
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 22
Table 5: Guidelines for the Treatment of Schizophrenia 23
Table 6: Leading Branded Treatments for Schizophrenia, 2013 29
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 29
Table 8: Chemical Classifications of FGAs 30
Table 9: Receptor Affinity Profiles for FGAs 31
Table 10: First-Generation Antipsychotics SWOT Analysis, 2013 32
Table 11: Product Profile - Abilify 35
Table 12: Abilify SWOT Analysis, 2014 38
Table 13: Product Profile - Saphris 39
Table 14: Saphris SWOT Analysis, 2013 41
Table 15: Product Profile - Clozaril 42
Table 16: Clozaril SWOT Analysis, 2014 43
Table 17: Product Profile - Fanapt 44
Table 18: Fanapt SWOT Analysis, 2014 46
Table 19: Product Profile - Latuda 47
Table 20: Latuda SWOT Analysis, 2014 48
Table 21: Product Profile - Zyprexa 50
Table 22: Zyprexa SWOT Analysis, 2014 53
Table 23: Product Profile - Invega 54
Table 24: Invega SWOT Analysis, 2013 56
Table 25: Product Profile - Seroquel 57
Table 26: Seroquel SWOT Analysis, 2013 58
Table 27: Product Profile - Risperdal 60
Table 28: Risperdal SWOT Analysis, 2013 62
Table 29: Product Profile - Geodon 63
Table 30: Geodon SWOT Analysis, 2013 64
Table 31: Unmet Needs - Current Level of Attainment 66
Table 32: Clinical Unmet Needs - Gap Analysis, 2013 71
Table 33: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014 76
Table 34: Pipeline Candidates in Development for Schizophrenia, 2014 77
Table 35: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013 78
Table 36: Product Profile - Aripiprazole Lauroxil 79
Table 37: Aripiprazole Lauroxil SWOT Analysis, 2014 83
Table 38: Product Profile - Cariprazine 84
Table 39: Cariprazine SWOT Analysis, 2014 87
Table 40: Product Profile - Brexpiprazole 88
Table 41: Brexpiprazole SWOT Analysis, 2014 90
Table 42: Product Profile - Zicronapine 91
Table 43: Zicronapine SWOT Analysis, 2014 93
Table 44: Product Profile - Bitopertin 94
Table 45: Bitopertin SWOT Analysis, 2014 96
Table 46: Product Profile - EVP-6124 97
Table 47: EVP-6124 SWOT Analysis, 2014 99
Table 48: Sales Forecast ($m) for Schizophrenia in the US, 2012-2022 101
Table 49: Key Events Impacting Sales for Schizophrenia in the US, 2012-2022 103
Table 50: Schizophrenia Market in the US - Drivers and Barriers, 2012-2022 103
Table 51: Key Launch Dates 122
Table 52: Key Patent Expirations 123

1.2 List of Figures

Figure 1: Schizophrenia - Pipeline Drugs by Target, 2014 74
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022 77
Figure 3: Sales for Schizophrenia in the US by Drug Class, 2012-2022 102

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.